mRNA
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
mRNAutilus: Multi-Objective-Guided Discrete Generation of mRNA with Optimized Therapeutic Properties
arXiv:2605.31296v1 Announce Type: cross Abstract: Therapeutic mRNA design requires coordinating multiple interacting sequence features across the full transcript, where codon usage, untranslated regions (UTRs), and their coupling jointly determine stability, translation efficiency, and protein expression. Here, we present mRNA generation via unrolled trajectories and informed latent updates (mRNAutilus), a framework for simultaneous codon optimization and de novo UTR design directly from...
mRNA-Encoded TLR5 Agonist as an Immune Adjuvant
Activation of innate immunity enhances adaptive immune responses and underlies the mechanism of action of vaccine adjuvants. First-generation mRNA vaccines lack a dedicated adjuvant, relying instead on the self-adjuvating properties of lipid nanoparticles (LNPs), and are thus expected to benefit from additional engagement of innate immune pathways not activated by LNPs. Among innate immune modulators, TLR5 agonists are particularly promising adjuvants due to their ability to induce a...
Experimental mRNA vaccine may protect against multiple Ebola viruses
Tests with rodents suggest an mRNA vaccine in development offers protection against three strains of Ebola virus, including the one behind the current crisis
A cancer vaccine made just for you. mRNA is back and it's fighting melanoma
A study finds that an mRNA vaccine is highly effective at preventing recurrence of this dangerous skin cancer, when used in combination with Keytruda, an immunotherapy drug.
Author Correction: PTC-bearing mRNA elicits a genetic compensation response via Upf3a and COMPASS components
Nature, Published online: 09 June 2026; doi:10.1038/s41586-026-10769-0Author Correction: PTC-bearing mRNA elicits a genetic compensation response via Upf3a and COMPASS components
Moderna gets $50 million to develop mRNA Ebola vaccine against Bundibugyo
The global health organization Coalition for Epidemic Preparedness Innovations (CEPI) announced Monday that it will "urgently accelerate development" of three vaccine candidates against Bundibugyo ebolavirus (BDBV), pledging a little over $60 million in the effort to extinguish an outbreak currently raging out of control in the Democratic Republic of the Congo. Under the plans, CEPI has committed up to $50 million to US-based Moderna for preclinical development and Phase 1 clinical testing...
TgmRHel drives unified RNA processing of coxI mRNA generated from a complex mitochondrial genomic context
The mitochondrial genome of Toxoplasma gondii is highly fragmented and recombination-prone, creating a structurally dynamic genetic landscape. How such a genome is used efficiently to produce functional mRNAs remains unclear: it is unknown whether transcription draws from many alternative genomic configurations or a restricted subset, and how any resulting precursor RNAs are processed into mature transcripts. More broadly, mitochondrial RNA processing mechanisms in this system are poorly...
DNMT mRNA stability and YB-1 cooperatively regulate ABCB1 to drive cisplatin chemoresistance in cholangiocarcinoma
Background and Aims: Intrahepatic cholangiocarcinoma (iCCA) is a tumor type with a high lethality due to late diagnosis and profound resistance to conventional chemotherapy. To date the molecular mechanisms underlying multidrug resistance remain poorly defined. Here, we integrate single-cell transcriptomics, clinicopathological analysis, and functional genomics to elucidate the molecular basis of cisplatin resistance in iCCA.
Collecting Duct-Targeted Lipid Nanoparticles Deliver Pkd2 mRNA to Restore Polycystin-2 and Attenuate ADPKD
Autosomal dominant polycystic kidney disease (ADPKD), a leading genetic cause of kidney failure, is caused by mutations in the PKD1 or PKD2 genes, resulting in functional polycystin 1 (PC1) or polycystin 2 (PC2) deficiency, and is characterized by progressive cyst expansion in the kidneys. However, no approved therapy directly restores polycystin expression, and current treatments target downstream pathways rather than the genetic defect. Gene replacement therapy offers a direct route to...
A-to-I mRNA editing recodes CqsA and affects T6SS-mediated killing in Vibrio
Adenosine-to-inosine (A-to-I) RNA editing alters genetic information post-transcriptionally, yet its ecological and evolutionary significance in bacteria remains largely unexplored. Here, we show that endogenous RNA editing has functional consequences in bacteria. Using Vibrio alginolyticus as a model, we identified 38 editing events - the highest number reported for any bacterium to date.